Stock Ratings / Health Care / KRMD / insiders

LUNG (38) SKYA (36) STIM (31) PYPD (33) ⌘ Pro Terminal →

KORU Medical Systems Inc. (KRMD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.23 +0.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.23

KORU Medical Systems Inc. (KRMD) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $149.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KRMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, KORU Medical Systems Inc. (NASDAQ: KRMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $3.23 (+0.31% 1D, market cap $149.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, KRMD ranks #382 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KRMD compare to LUNG and SKYA in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), KRMD carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of -28.7%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $135.9M) and SKYA (SkyAI Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M). Among the 5-stock peer group, KRMD leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KRMD?

▼

Per KRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000704440), KORU Medical Systems Inc. generated $41.1M in revenue (+22.2% YoY), -$2.6M in net income, and $462.4K in free cash flow against $28.2M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.23 (-0.13%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-4.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRMD)Realized 20D OHLCV Swing Band: ±9.6%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY KRMD SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (33% of score)

Altman Z-Score 8.05 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 1.1% FCF Margin ($462.4K FCF) & 62.3% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.96+1.4% Next Q

Q2 (-2Q)

Grade D$3.00+5.7% Next Q

Q3 (-1Q)

Grade D$3.17+1.9% Next Q

Current

Grade D$3.23-5.6% Hist 90D α

Trajectory: D (40) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KRMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KRMD currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.13) and Max Pain ($3.39) forces dealer call-delta covering toward $6.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

KRMD Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (KRMD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on KRMD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRMD)

✓Walkthrough of KRMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.05%📐 HORIZONTAL RANGE

2026-10-30O $3.24H $3.24L $2.99C $3.23VOL 165.2K

RES: $4.80SUP: $2.67SMA50: $3.13SMA200: $4.02

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KRMD Butterfly Map → + Track KRMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRMD)

Health Care Rank #382 of 1016 ⚔️ LUNG vs KRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KRMD vs. LUNG, SKYA, STIM, PYPD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, KORU Medical Systems Inc. (KRMD) ranks #382 by composite RQD confidence (48/100, grade D) and #610 by equity capitalization ($149.1M). Within this direct 5-issuer industry benchmark cohort, KRMD leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. KRMD currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KRMD ACTIVE KORU Medical Systems Inc.	D	48/100	—	62.3%	-28.7%	+0.31%	$149.1M	Benchmark Subject
LUNG Pulmonx Corporation	D-	38/100	—	74.2%	-35.0%	+25.60%	$135.9M	/lung-vs-krmd →
SKYA SkyAI Inc.	D-	36/100	—	-30.0%	-35.0%	-0.68%	$126.7M	/skya-vs-krmd →
STIM Neuronetics Inc.	E	31/100	—	48.5%	-35.0%	+5.31%	$181.3M	/stim-vs-krmd →
PYPD PolyPid Ltd.	E	33/100	—	—	-35.0%	-3.29%	$113.5M	/pypd-vs-krmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000704440

In its most recent audited fiscal period (FY2025, filed 2025-12-31), KORU Medical Systems Inc. (KRMD) reported GAAP revenue of $41.1M (+22.2% vs. FY2024 revenue of $33.6M , and +44.2% cumulative change since FY2023) , GAAP net income of -$2.6M, operating cash flow of $462.4K, and free cash flow of $462.4K (+244.6% YoY). On the balance sheet, KRMD closed FY2025 with $28.2M in total assets against $0 in total debt (Altman Z-Score: 8.05, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$41.1M	-$2.6M	$462.4K	$462.4K	$28.2M	—
FY2024 (FY)	2024-12-31	$33.6M	-$6.1M	-$319.7K	-$319.7K	$27.2M	—
FY2023 (FY)	2023-12-31	$28.5M	-$13.7M	-$4.9M	-$4.9M	—	—

3. KRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KRMD compare to LUNG and SKYA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KRMD?

Where is KRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

KRMD last traded at $3.23 (+0.31% on volume of 84,326 shares), positioning the stock +3.19% above its 50-day simple moving average ($3.13) and -19.65% below its 200-day simple moving average ($4.02). Across its 52-week range of $2.86 to $6.61, KRMD sits at the 9.9% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($2.92 to $3.54).

KRMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are KRMD insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies KRMD leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: KRMD RQD Cockpit KRMD 12M Forecast KRMD Earnings & Move KRMD Dividends & DRIP KRMD Insiders & 13F KRMD Whale Options KRMD Profit Sankey KRMD News & Why